Key Developments: Cell Therapeutics Inc (CTIC.O)

CTIC.O on Consolidated Issue listed on NASDAQ Capital Market

3.29USD
23 Apr 2014
Price Change (% chg)

$-0.04 (-1.20%)
Prev Close
$3.33
Open
$3.30
Day's High
$3.31
Day's Low
$3.21
Volume
876,202
Avg. Vol
4,970,894
52-wk High
$4.25
52-wk Low
$0.97

Search Stocks

Latest Key Developments (Source: Significant Developments)

Cell Therapeutics Inc gives FY 2014 EBIT guidance above analysts' estimates
Tuesday, 4 Mar 2014 04:00pm EST 

Cell Therapeutics Inc:Expects FY 2014 loss from operations is expected to be about $45 million to $50 million.FY 2014 EBIT of $(56) million - Thomson Reuters I/B/E/S.  Full Article

NICE publishes final guidelines of Cell Therapeutics Inc's pixuvri (pixantrone)
Thursday, 27 Feb 2014 02:09am EST 

Cell Therapeutics Inc:Announces that NICE - (National Institute for Health and Care Excellence), has published the final guidelines that define Pixuvri (pixantrone) cost-effective and will recommend the prescription as monotherapy in the treatment of adult patients with non-Hodgkin lymphoma (NHL), aggressive B-cell.  Full Article

Cell Therapeutics Inc announces phase 2 trial evaluating pacritinib for patients with relapsed flt3 positive acute myeloid leukemia
Thursday, 30 Jan 2014 01:30am EST 

Cell Therapeutics Inc:Announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene.Mutation of the FLT3 gene is found in about one-third of AML patients and is an independent risk factor for poor prognosis.Says the trial is being conducted by the AML Working Group of the National Cancer Research Institute Haematological Oncology Study Group in Acute Myeloid Leukemia (AML) and high risk Myelodysplastic Syndrome (MDS) under the sponsorship of Cardiff University and supported by Cancer Research UK.Says the trial management group is lead by Professor Alan K. Burnett, Head of Haematology in the Department of Medical Genetics, Haematology and Pathology at the School of Medicine at Cardiff University.  Full Article

Cell Therapeutics Inc says GOG completes patient enrollment in GOG-0212 Phase 3 clinical trial of Paclitaxel Poliglumex (Opaxio) as maintenance therapy in ovarian cancer
Tuesday, 28 Jan 2014 01:31am EST 

Cell Therapeutics Inc:Says Gynecologic Oncology Group (GOG) informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex (Opaxio) as maintenance therapy in ovarian cancer.Says the trial is being conducted and managed by the GOG, which is one of the National Cancer Institute‚Äôs (NCI) funded cooperative cancer research groups focused on the study of gynecologic malignancies.Says the GOG-0212 study is a randomized, multicenter, open label Phase 3 trial of either monthly Opaxio or paclitaxel for up to 12 consecutive months compared to surveillance among women with advanced ovarian cancer who have no evidence of disease following first-line platinum-taxane based therapy.  Full Article

Cell Therapeutics Inc reaches agreement to reacquire rights to two anti-cancer compounds from Novartis AG
Monday, 13 Jan 2014 01:31am EST 

Cell Therapeutics Inc:Announces that it has reached an agreement with Novartis AG to reacquire rights to two anti-cancer compounds - pixantrone (PIXUVRI) and paclitaxel poliglumex (OpaxioTM).Says under the terms of the previous agreement, CTI has been responsible for development and commercialization activities and expenses for both compounds to date.Says upon the effective date of termination, CTI will regain all rights that had been granted to Novartis.  Full Article

Cell Therapeutics Inc receives positive final appraisal determination from NICE
Tuesday, 7 Jan 2014 01:31am EST 

Cell Therapeutics Inc:Announces that the National Institute for Health and Care Excellence (NICE), in the United Kingdom (UK), has issued its Final Appraisal Determination (FAD) for PIXUVRI (pixantrone).Says positive final draft guidance determines PIXUVRI cost effective and recommends funding the treatment as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma which includes diffuse large B-cell lymphoma (DLBCL).  Full Article

Cell Therapeutics Inc announces removal of the partial clinical hold on Tosedostat
Thursday, 2 Jan 2014 01:30am EST 

Cell Therapeutics Inc:Says it has received notification from the U.S. FDA that the partial clinical hold on tosedostat (IND 075503) has been removed and all studies underway may continue.Says Tosedostat is currently being studied in the United States and European Union in investigator-sponsored and cooperative group-sponsored Phase 2 trials in elderly patients with newly diagnosed and relapsed acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).  Full Article

Cell Therapeutics Inc receives remaining $5 mln under existing loan financing agreement
Wednesday, 18 Dec 2013 01:30am EST 

Cell Therapeutics Inc:Says it has received the remaining $5 mln from Hercules Technology Growth Capital, Inc. available under the existing loan agreement that was established in Mar. 2013.  Full Article

Cell Therapeutics Inc announces interim results from phase 2 tosedostat trial
Tuesday, 10 Dec 2013 01:30am EST 

Cell Therapeutics Inc:Says promising interim results from an investigator-initiated Phase 2 clinical trial of tosedostat in combination with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).Says phase 2 trial was designed to test the efficacy of tosedostat in combination with low intensity therapy for older patients with previously untreated AML or high-risk MDS not considered candidates for standard intensive therapy.Says Patients were randomized to treatment with tosedostat in combination with either cytarabine or decitabine.Says 14 out of 26 (54 pct) patients in this cohort had either a complete response (CR; n=10, 39 pct) or complete response with incomplete blood count recovery (CRi; n=4, 15 pct).Says seven (50 pct) of the 14 CR/CRi were achieved in patients with poor-risk cytogenetic features.Says study achieved its primary objective with 21 (82 pct) patients alive at four months.  Full Article

Cell Therapeutics Inc says it reached agreement on pricing of PIXUVRI (pixantrone) in Germany with GKV-SV
Wednesday, 4 Dec 2013 01:31am EST 

Cell Therapeutics Inc:Says it concluded an agreement with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) in Germany on pricing of PIXUVRI (pixantrone).Says PIXUVRI is a medicinal product approved in the European Union for patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy.  Full Article

BRIEF-Cell Therapeutics up 4.4 percent premarket

NEW YORK, Jan 21 - Cell Therapeutics Inc : * Up 4.4 percent to $3.80 in premarket

Search Stocks